Accueil   Diary - News   All news Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes

Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes

 

• Adocia has developed an innovative hydrogel to host and protect pancreatic cell implants

• This hydrogel scaffold containing pancreatic cells could restore glycemic control without requiring insulin injection and immunosuppressant drugs

• An academic collaboration with Pr. Pattou’s Inserm Team, worldwide leader of islet transplant has been established to develop this product in animal models and ultimately in human

 

 

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced today it is developing a hydrogel scaffold that hosts and protects pancreatic β cells for replacement of the missing cells of people with type 1 diabetes.

 

“Capitalizing on our expertise in regenerative medicine and diabetes, our multidisciplinary team has developed a scaffold for cells with the aim of being transformed into an organoid controlling glycemia. The collaboration with the team of experts of Professor Pattou has created great momentum and the first results obtained in small animals are really exciting,” said Olivier Soula, Deputy CEO and Director of R&D.

 

 

Read the press release